Filtered By:
Specialty: Research
Drug: Temodar
This page shows you your search results in order of date.
Order by Relevance | Date
Total 29 results found since Jan 2013.
A sequential targeting strategy interrupts AKT-driven subclone-mediated progression in glioblastoma
CONCLUSION: Drug-resistant ALDH1A1+/pAKT+ subclones accumulate in patient tissues upon adaptation to temozolomide therapy. These subclones may therefore represent a dynamic target in glioblastoma. Our study proposes the combination of temozolomide and AKT inhibitors in a sequential treatment schedule as a rationale for future clinical investigation.PMID:36239995 | DOI:10.1158/1078-0432.CCR-22-0611
Source: Clin Med Res - October 14, 2022 Category: Research Authors: Sied Kebir Vivien Ullrich Pia Berger Celia Dobersalske Sarah Langer Laur èl Rauschenbach Daniel Trageser Andreas Till Franziska K Lorbeer Anja Wieland Timo Wilhelm-Buchstab Ashar Ahmad Holger Fr öhlich Igor Cima Shruthi Prasad Johann Matschke Verena Jen Source Type: research
Matteucinol combined with temozolomide inhibits glioblastoma proliferation, invasion, and progression: an in vitro, in silico, and in vivo study
In conclusion, Mat-TMZ can be a good candidate for pharmacokinetic studies in view of clinical use for the treatment of glioblastoma.PMID:36000612 | PMC:PMC9394692 | DOI:10.1590/1414-431X2022e12076
Source: Braz J Med Biol Res - August 24, 2022 Category: Research Authors: J B Netto E S A Melo A G S Oliveira L R Sousa L R Santiago D M Santos R C R Chagas A S Gon çalves R G Thom é H B Santos R M Reis R I M A Ribeiro Source Type: research
